Burney Co. Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Burney Co. increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 113.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 23,922 shares of the biotechnology company’s stock after acquiring an additional 12,705 shares during the period. Burney Co.’s holdings in United Therapeutics were worth $8,441,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new stake in United Therapeutics during the 3rd quarter valued at approximately $33,000. Brooklyn Investment Group purchased a new position in United Therapeutics during the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics in the 3rd quarter valued at $82,000. Values First Advisors Inc. purchased a new stake in United Therapeutics in the 3rd quarter worth $90,000. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in shares of United Therapeutics by 14.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 42 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now owns 6,978 shares in the company, valued at approximately $2,442,300. The trade was a 52.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $364.62, for a total value of $3,646,200.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $939,625.74. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,630 shares of company stock valued at $54,371,916 in the last 90 days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $367.99 on Wednesday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The stock has a market cap of $16.43 billion, a price-to-earnings ratio of 16.16, a P/E/G ratio of 1.05 and a beta of 0.57. The stock’s 50 day moving average price is $370.22 and its 200-day moving average price is $352.98.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the firm posted $5.38 earnings per share. As a group, analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.